Not sure if this was posted, but another potential
Post# of 148169
(Total Views: 476)
Posted On: 03/05/2021 11:51:19 AM
Not sure if this was posted, but another potential treatment bites the dust...
Apellis Shelves Study Of APL-9 In Severe COVID-19 Patients
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) said it will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19. The decision followed an interim review of mortality data from the Phase 1/2 study by an independent data monitoring committee, which found no meaningful reduction in the overall mortality rate in patients treated with APL-9 in combination with standard of care therapy compared to standard of care alone. No safety signals were observed by the DMC.
Apellis Shelves Study Of APL-9 In Severe COVID-19 Patients
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) said it will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19. The decision followed an interim review of mortality data from the Phase 1/2 study by an independent data monitoring committee, which found no meaningful reduction in the overall mortality rate in patients treated with APL-9 in combination with standard of care therapy compared to standard of care alone. No safety signals were observed by the DMC.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼